BioPharmSignal logoBioPharmSignal

Biotech News

Delcath Systems to Participate at the H.C. Wainwright 4th Annual BioConnect Investor Conference

Delcath Systems (DCTH)Delcath SystemsConference / presentation

QUEENSBURY, N.Y. --(BUSINESS WIRE)--May 12, 2026-- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that management will be attending the H.C.

Related news

DCTHDelcath Systems2026-07-28 20:01 EST

Delcath Systems to Participate at the Canaccord Genuity 46th Annual Growth Conference

LMATLeMaitre Vascular2026-08-06 21:15 EST

LeMaitre to Participate in the 11th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference

REGNRegeneron Pharmaceuticals2026-08-19 20:05 EST

Regeneron Announces Investor Conference Presentations

DCTHDelcath Systems2026-08-06 12:01 EST

Delcath Systems Reports Second Quarter 2026 Results and Business Highlights

RVMDRevolution Medicines2026-06-24 23:31 EST

Revolution Medicines to Present Clinical Data from RAS(ON) Inhibitor Combination Trials in Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026

IARTIntegra LifeSciences2026-06-15 12:30 EST

Integra LifeSciences to Present at the 2026 Truist Securities MedTech Conference

TMCITreace Medical Concepts2026-06-11 20:05 EST

Treace to Present at the Sidoti Small Cap Conference

PRCTPROCEPT BioRobotics2026-08-17 12:00 EST

PROCEPT BioRobotics® to Attend the Baird 2026 Global Healthcare Conference on September 15, 2026

IARTIntegra LifeSciences2026-06-02 11:30 EST

Integra LifeSciences to Present at the 2026 Jefferies Global Healthcare Conference

ZNTLZentalis2026-07-17 20:15 EST

Zentalis Pharmaceuticals to Present at the European Society for Medical Oncology (ESMO) Congress 2026

View all latest news

Delcath Systems

Interventional Oncology Delcath Systems develops liver-directed therapies for primary and metastatic liver cancers. Its technology isolates hepatic circulation so high-dose chemotherapy can be delivered to the liver while limiting systemic exposure. HEPZATO KIT HEPZATO KIT combines melphalan with the company's percutaneous...

Recent company news

DCTHDelcath Systems2026-08-06 12:01 EST

Delcath Systems Reports Second Quarter 2026 Results and Business Highlights

DCTHDelcath Systems2026-07-28 20:01 EST

Delcath Systems to Participate at the Canaccord Genuity 46th Annual Growth Conference

DCTHDelcath Systems2026-07-23 20:01 EST

Delcath Systems to Host Second Quarter 2026 Earnings Call

DCTHDelcath Systems2026-07-16 20:01 EST

Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

DCTHDelcath Systems2026-07-09 12:00 EST

Delcath Systems Announces First Patient Dosed in Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Breast Cancer

Stock data

Close
17.14 USD
Market cap
363.51M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States